President John Dramani Mahama has urged Ghanaians to participate in clinical trials as the country intensifies efforts to develop and manufacture its own vaccines.
He said public participation in clinical research was essential to building Ghana’s vaccine production capacity and reducing dependence on foreign suppliers.
Speaking at the commissioning of vaccine research facilities at the Noguchi Memorial Institute for Medical Research, President Mahama warned against misinformation surrounding clinical trials.
He recalled how an attempt to conduct Ebola vaccine trials in the Volta Region faced public opposition following claims that residents were being used as guinea pigs.
The trials were eventually moved to another African country, depriving Ghanaian researchers of an opportunity to contribute to the process.
President Mahama said such fears could undermine the country’s ambitions to become a major vaccine manufacturing centre.
“We develop vaccines and an essential part of developing vaccines is clinical trials. And clinical trials are like immunization,” he said.
He explained that clinical trials allow researchers to study how the human body responds to vaccines before they are approved for wider use.
The President stressed that Ghana could not develop its own vaccines if citizens refused to participate in the necessary research.
“Nobody will do the clinical trials for us to develop vaccines in our country. And so that is my message to you,” he added.
He also recalled the COVID-19 pandemic, which exposed weaknesses in global vaccine supply chains and left many African countries struggling to access vaccines.
“The Western countries satisfied their domestic demand before they passed on the leftovers to us,” he said.
Meanwhile, President Mahama disclosed that Ghana was among only five African countries using innovative mRNA technology to research and develop new vaccines.
The newly established mRNA and protein laboratories will provide local scientists with facilities to conduct research, test ideas and collaborate with international partners.
He said the facilities would support Ghana’s long-term ambition to achieve vaccine self-sufficiency and strengthen its health security.
President Mahama further disclosed that two Ghanaian pharmaceutical companies, Atlantic Life Sciences and DEK Laboratories, had been selected to develop vaccines.
Government has also allocated $1 billion to the pharmaceutical sector under the New Economy’s Seventh Pillar. The investment will support pharmaceutical and biomanufacturing hubs in the Eastern, Central and Volta regions.
He added that government would spend $46 million this year to procure vaccines for child immunisation.
The President said these investments would help Ghana prepare for future disease outbreaks and position the country as a pharmaceutical hub for West Africa and the wider continent.

































